Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation

Background: Immune checkpoint inhibitors (ICIs) have become an effective treatment option for cancer. KRAS, EGFR and TP53 are common mutated oncogenes in cancer whose single gene status may predict the therapeutic effect of clinical ICIs. In this efficacy evaluation, we aimed to clarify whether the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shui, Geng, Shuai, Shi, Ning, Zhang, Lili, Xue, Wenxin, Li, Yiwen, Jiang, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984186/
https://www.ncbi.nlm.nih.gov/pubmed/35401171
http://dx.doi.org/10.3389/fphar.2022.878540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984186/
https://www.ncbi.nlm.nih.gov/pubmed/35401171
http://dx.doi.org/10.3389/fphar.2022.878540

Ejemplares similares